Pharmaceuticals & Therapeutics

The nation's top IV therapy franchise reports record growth, but its expansion highlights a booming wellness industry navigating a complex regulatory landscape.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

Beverly Hills Plastic Surgery® is moving beyond aesthetics with its "Eternal G.L.O.W." series, a year-long program focused on holistic health.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

New clinical data reveals a minimally invasive spine implant significantly cuts pain, improves function, and reduces opioid use for SI joint dysfunction.

Ernexa Therapeutics secures crucial funding for its cancer therapy pipeline, but the dilutive offering sends its stock plunging more than 50%.

EMD Serono and the Trump Administration launch a new program offering massive discounts on IVF drugs, bringing hope to millions of aspiring parents.

Aucta Pharma launches two rare disease drugs, PYQUVI and ZELVYSIA, betting on a 'branded-generic' model to navigate highly competitive markets.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Stunning real-world data shows Iovance's Amtagvi is more effective in earlier melanoma treatment, potentially changing clinical practice and offering new hope.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

Employers are ditching fragmented vendors for unified platforms that promise to cut costs and complexity, fueling a surge in healthcare technology M&A.

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

A new study reveals why Sickle Cell Disease patients suffer from frequent crises and rely on pain pills, even with awareness of multi-million dollar cures.